Abstract
Patients with advanced cholangiocarcinoma (CCA) have limited treatment options. Fibroblast growth factor receptor (FGFR) fusions are found in 10-16% of patients with CCA. Infigratinib is a selective FGFR2 inhibitor. The aim of this study was to evaluate the efficacy and safety of infigratinib for the treatment of advanced CCA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
